Randomised Controlled Trial Assessing the Impact of Genital Herpes Suppressive Therapy on HIV Shedding
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
- Study ID
- NCT00158509
- Phase
- PHASE2
- Status
- Completed
Conditions
- HIV Infection
- Herpes Genitalis
Eligibility Criteria
- Sex
- FEMALE
- Age
- 16 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Valacyclovir — DRUG
Study Details
Genital herpes is a long-life sexually transmitted diseases which infects a large proportion of women in Africa. Its clinical symptoms are painful sores on the genitals, which heals after a few days. HIV infection can worsen genital herpes. In turn, it is possible that genital herpes increases the quantity of HIV secreted at the genital level in women infected by the 2 viruses. This study is dedicated to verify this hypothesis.
Key Dates
- Start date
- Aug 31, 2004
- Status verified
- Jun 2006
- Completion
- Jul 31, 2005
Study Design
- Enrollment
- 215 participants
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- PREVENTION
Primary Outcome Measure
To assess the impact of HSV-2 suppressive therapy on HIV shedding among co-infected women taking highly active antiretroviral therapy (HAART) or not needing HAART
Related Studies
- Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV RemissionPHASE1/PHASE2 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · La Jolla, California
- Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility StudyRecruiting · AIDS Malignancy Consortium · La Jolla, California
- Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin LymphomaPHASE1 · Recruiting · AIDS Malignancy Consortium · Duarte, California
- The Role of the Gastrointestinal-associated Lymphoid Tissue in the Cure of HIV InfectionRecruiting · Icahn School of Medicine at Mount Sinai · New York, New York